title: [Progress in face transplantation].
abstract: Vascularised composite allotransplantation (VCA) is utilised for restoration of complex defects. In this context, restoration describes the replacement of destroyed tissue by identical anatomic structures. Up to date, over 150 VCAs including 31 face transplantations have been performed worldwide. Face transplantation is a life giving, rather than life saving procedure that is intended to significantly improve the patient's quality of life. Safe revascularisation as well as aesthetic and functional reintegration are the ultimate goals of face transplantation. The necessary lifelong immunosuppression with potentially life-threatening side effects imposes the need for a very strict risk-benefit ratio assessment and currently limits the indications of face transplantation. Different transplant centres use different protocols for induction and maintenance immunosuppression. Skin is the most immunogenic part of the vascularised composite allograft and has been the focus of intensive research efforts in order to replicate the success of immunosuppressive regimens for solid organ transplantation. Organ preservation during transfer from donor to recipient is another important field of research within VCA. The general public's originally rejecting attitude towards non-lifesaving VCA procedures has changed towards a general acceptance following the publication of promising results after the first cases of face transplantation. Further improvements of surgical techniques and immunosuppressive strategies will be important to drive these young and exciting procedures forward in the future.
authors.affiliation: Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
authors.forename: M
authors.initials: M
authors.lastname: Kueckelhaus
authors.affiliation: Klinik für Plastische Chirurgie und Schwerbrandverletzte, Handchirurgiezentrum, Operatives Referenzzentrum für Gliedmaßentumore, BG Universitätsklinik Bergmannsheil, Bochum.
authors.forename: M
authors.initials: M
authors.lastname: Lehnhardt
authors.affiliation: Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
authors.forename: S
authors.initials: S
authors.lastname: Fischer
authors.affiliation: Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
authors.forename: E
authors.initials: E
authors.lastname: Eriksson
authors.affiliation: Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
authors.forename: B
authors.initials: B
authors.lastname: Pomahac
authors.affiliation: Klinik für Plastische Chirurgie und Schwerbrandverletzte, Handchirurgiezentrum, Operatives Referenzzentrum für Gliedmaßentumore, BG Universitätsklinik Bergmannsheil, Bochum.
authors.forename: T
authors.initials: T
authors.lastname: Hirsch
mesh_terms: D004954:Esthetics; D054445:Facial Transplantation / Q000639:trends*; D005544:Forecasting; D005858:Germany; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000639:trends; D008866:Microsurgery / Q000379:methods / Q000639:trends; D009926:Organ Preservation / Q000379:methods / Q000639:trends; D018579:Patient Selection; D016038:Skin Transplantation / Q000379:methods / Q000639:trends